MHRA Alerts
Direct-acting oral anticoagulants (DOACs): paediatric and renal impairment – Medicines and Healthcare products Regulatory Agency
Finasteride and Dutasteride update - by the Medicines and Healthcare products Regulatory Agency (MHRA)
Epimax Ointment and Epimax Paraffin-Free Ointment: reports of ocular surface toxicity and ocular chemical injury – Medicines and Healthcare products Regulatory Authority advice
Gabapentinoids (Pregabalin/Gabapentin), Benzodiazepines and Z-Drugs – Medicines and Healthcare products Regulatory Authority advice
GLP-1 medicines (weight loss drugs) and contraception – Medicines and Healthcare products Regulatory Agency advice
Insulin pumps and continuous glucose monitoring (CGM) equipment: guidance for users on reporting suspected adverse incidents and safety concerns to the MHRA’s Yellow Card scheme
Mesalazine and idiopathic intracranial hypertension – Medicines and Healthcare products Regulatory Agency advice
Nitrofurantoin: risk to lungs and liver with long term use – Medicines and Healthcare products Regulatory Agency advice
Thiopurines and pregnancy – Medicines and Healthcare products Regulatory Agency advice
Topiramate risks in pregnancy – Medicines and Healthcare products Regulatory Authority advice
Warfarin and tramadol risk of interaction – Medicines and Healthcare products Regulatory Authority advice
